The long-term, exclusive pharmaceutical category agreement is ... and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission.

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing ...

In 2005, Sandoz became the world leader in generic pharmaceuticals after acquiring Germany's Hexal AG and US-based Eon Labs. The same year, Novartis acquired the North American over-the-counter ...

UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Novel Modes of Treatment and Drugs Spur the Demand in the Immuno-oncology Market: Fact Report ROCKVILLE, MD, UNITED STATES, March 13, ...

Moderna Inc., a biotechnology and pharmaceutical company reorienting its business for a post-pandemic age, awarded almost $17 ...

Pertussis Treatment Market Pertussis Medications and Vaccinations Leading Therapeutic Approaches Driving Stance of Companies in the Market: ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Strategic Company DecisionCuratis Announces Formation of Distinguished Advisory Board 11.03.2025 / 07:00 CET/CESTMEDIA RELEASELiestal, Switzerland, 11 March 2025: Curatis Holding (SIX:CURN) announces ...